Table 1.
Patient characteristics by country prior to CAR-T cell treatment
| Cohorts by country | |||
|---|---|---|---|
| Characteristic | Total cohort (N=172) | Germany (N=66) | US (N=106) |
| Age | |||
| Median (range) - yr | 62 (24-88) | 63 (31-82) | 62 (24-88) |
| ≥65 yr - no(%) | 75 (43.6) | 29 (43.9) | 46 (43.4) |
| Gender - no (%) | |||
| Female | 55 (32.0) | 20 (30.3) | 35 (33.0) |
| Male | 117 (68) | 46 (60.7) | 71 (67.0) |
| Diagnosis - no (%) | |||
| DLBCL/TFL | 162 (94.2) | 63 (95.4) | 99 (93.4) |
| PMBCL | 4 (2.3) | 1 (1.5) | 3 (2.8) |
| Richter TCLL | 3 (1.7) | 1 (1.5) | 2 (1.9) |
| TMZL | 3 (1.7) | 1 (1.5) | 2 (1.9) |
| CAR-T product - no (%) | |||
| Axi-cel | 122 (70.9) | 30 (47.0) | 91 (85.8) |
| Tisa-cel | 49 (28.5) | 34 (51.5) | 15 (14.2) |
| Liso-cel | 1 (0.6) | 1 (1.5) | 0 |
| Center - no (%) | |||
| Germany | 66 (38.4) | Heidelberg | MDACC |
| United States | 106 (61.6) | 21 (31.8) | 59 (55.7) |
| Munich | Moffitt | ||
| 41 (62.1) | 47 (44.3) | ||
| Regensburg | |||
| 4 (6.1) | |||
| ECOG performance-status score - no (%) | |||
| 0 | 52 (30.2) | 30 (45.5) | 22 (20.8) |
| 1 | 97 (56.4) | 27 (40.9) | 70 (66.0) |
| 2 | 18 (10.5) | 6 (9.1) | 12 (11.3) |
| 3 | 5 (2.9) | (4.5) | 2 (1.9) |
| Ann Arbor lymphoma staging system - no (%) | |||
| Stage I/II | 41 (23.8) | 22 (33.3) | 19 (17.9) |
| Stage III/IV | 131 (76.2) | 44 (66.7) | 87 (82.1) |
| Bulky disease - no (%) | |||
| ≥10 cm | 20 (12.5) | 9 (13.6) | 11 (11.7) |
| Missing (no) | 12 | 12 | |
| Bridging therapy - no. of pat. (%) | 109 (65.3) | 54 (81.8) | 55 (54.5) |
| Missing (no) | 5 | 5 | |
| Prior therapies - no (%) | |||
| 1 - 3 | 101 (61.2) | 38 (61.3) | 63 (61.2) |
| 4 - 6 | 61 (37.0) | 23 (37.1) | 38 (36.9) |
| 7 - 9 | 3 (1.9) | 1 (1.6) | 8 (7.8) |
| Missing (no) | 7 | 4 | 3 |
Legend: DLBCL, diffuse large B cell lymphoma; TFL, transformed follicular lymphoma; PBMCL: primary mediastinal B cell lymphoma; TCLL; transformed chronic lymphocytic leukaemia; TMZL: transformed marginal zone lymphoma.